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Abstract
Background: Administrative claims are a rich source of information for epidemiological and
health services research; however, the ability to accurately capture specific diseases or
complications using claims data has been debated. In this study, the authors examined the validity
of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis
codes for the identification of hyponatremia in an outpatient managed care population.
Methods: We analyzed outpatient laboratory and professional claims for patients aged 18 years
and older in the National Managed Care Benchmark Database from Integrated Healthcare
Information Services. We obtained all claims for outpatient serum sodium laboratory tests
performed in 2004 and 2005, and all outpatient professional claims with a primary or secondary
ICD-9-CM diagnosis code of hyponatremia (276.1).
Results:  A total of 40,668 outpatient serum sodium laboratory results were identified as
hyponatremic (serum sodium < 136 mmol/L). The sensitivity of ICD-9-CM codes for hyponatremia
in outpatient professional claims within 15 days before or after the laboratory date was 3.5%. Even
for severe cases (serum sodium ≤ 125 mmol/L), sensitivity was < 30%. Specificity was > 99% for all
cutoff points.
Conclusion: ICD-9-CM codes in administrative data are insufficient to identify hyponatremia in an
outpatient population.
Background
Hyponatremia, defined as an abnormally low level of
serum sodium, is the most frequently observed electrolyte
disorder in the United States and is associated with signif-
icant morbidity and mortality in patients with heart fail-
ure [1,2], myocardial infarction [3,4], and liver cirrhosis
[5,6], as well as in the hospitalized elderly population at
large [7]. Among general acute care patients, the preva-
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lence of hyponatremia is estimated to be approximately
1% [8,9]. However, much higher rates–ranging from 18%
to 30%–have been observed among elderly nursing home
residents [10] and in intensive care settings [11]. Little is
known about the prevalence of hyponatremia in outpa-
tient settings or in the general population.
Administrative claims data are a rich source of informa-
tion for epidemiological and health services research.
With increasing frequency, researchers are turning to
administrative claims data to ascertain information about
patient outcomes and hospital quality [12-19]. However,
the ability to accurately capture specific diseases or com-
plications using claims data has been a subject of consid-
erable debate [20-24].
Most validation studies of diagnosis and procedure codes
have relied on retrospective chart review as the source of
comparative information. Using medical record review as
the gold standard, Quan et al [25] found that the validity
of International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes for invasive or
major surgical procedures in inpatient discharge claims
was high; however, codes for routine procedures were
often inaccurate or incomplete. Geraci et al [26] used the
same method to assess the validity of 30 ICD-9-CM codes
for common in-hospital complications as observed in
patient discharge records from nine hospitals. They found
an overall sensitivity of 34% and a positive predictive
value of 32%. A handful of studies have used laboratory
information to validate administrative claims codes. Wei
and Walsh [27] compared managed care claims data with
laboratory results and found that less than 25% of female
beneficiaries with a positive test for chlamydia were coded
as such. In another study, researchers used clinical, radio-
logical, and laboratory data to assess the validity of ICD-9
codes for the diagnosis of gout in an ambulatory managed
care population and found a positive predictive value of
61% [28].
To our knowledge, there has been only one published
study of the validity of ICD-9-CM codes for the diagnosis
of hyponatremia. Movig et al [29] compared inpatient
hospital discharge records with inpatient laboratory data
and reported a sensitivity of 30% for even the strictest def-
inition of hyponatremia (≤ 115 mmol/L). Positive predic-
tive value for laboratory results showing serum sodium ≤
135 mmol/L was 91.7%. The study did not address the
validity of coding for hyponatremia outside the inpatient
setting. Therefore, we sought to examine the validity of
ICD-9-CM diagnosis codes for the identification of
hyponatremia in an outpatient managed care population.
Methods
Data source
We used data from the National Managed Care Bench-
mark Database from Integrated Healthcare Information
Services (IHCIS; Waltham, MA). The database includes
complete medical and eligibility data from over 30 health
plans covering more than 25 million lives in the United
States. Outpatient laboratory data are available for
approximately 10% of members, and outpatient phar-
macy information is available for 90% of members. Labo-
ratory tests performed during inpatient hospitalizations
are not collected in the database. To protect member con-
fidentiality, IHCIS removed all direct identifiers.
Claim identification
We limited the analysis to claims filed in 2004 and 2005
for members aged 18 years and older. We obtained all
claims for outpatient serum sodium laboratory tests per-
formed between January 1, 2004, and December 31,
2005. Serum sodium values < 8 mmol/L were excluded (n
= 1854) because these were considered data errors. All
remaining values were ≥ 100 mmol/L. When multiple
serum sodium tests were performed on the same day, we
retained the highest value for the analysis. We also
obtained all outpatient professional claims incurred in
2004 and 2005 with a primary or secondary ICD-9-CM
diagnosis code of hyponatremia (276.1).
For each claim, members were required to have had con-
tinuous eligibility for at least 60 days before and 15 days
after the claim date of service. Because this database repre-
sents a transient managed care population with a great
deal of movement into and out of plans, we chose a 60-
day period of observation prior to the serum sodium lab-
oratory test so that we might still observe comorbid claims
but not reduce the study population substantially by
requiring a lengthy period of pretest eligibility. Multiple
successive periods of eligibility, defined as an observed
coverage end date followed immediately by a new cover-
age start date, were considered switches in insurance prod-
uct and not a discontinuation of coverage; therefore, such
changes were not considered an interruption in coverage
but rather a single, continuous period of eligibility.
We excluded members with a professional claim for dial-
ysis in 2004 or 2005. We also excluded members with
serum/plasma triglycerides > 400 mg/dL as measured 15
days before or after the reference serum sodium date, due
to the possibility that any observed changes in serum
sodium were related to pseudohyponatremia. If blood
glucose was > 300 mg/dL as measured 15 days before or
after the reference serum sodium lab date, we adjusted the
serum sodium laboratory result by a factor of 1.6
(adjusted value = original value + ([glucose – 100]/100) ×
1.6) [30].BMC Nephrology 2008, 9:5 http://www.biomedcentral.com/1471-2369/9/5
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We reviewed inpatient, outpatient, and professional
claims for evidence of underlying comorbid conditions
within the 60-day period before through 15 days after the
reference serum sodium date. Specifically, we searched for
evidence of liver cirrhosis (ICD-9-CM code 572.4); con-
gestive heart failure (428.0); nephritis, nephrotic syn-
drome, and nephrosis (580–589); and syndrome of
inappropriate secretion of antidiuretic hormone (253.6).
In addition, we identified comorbid conditions using the
coding algorithms described by Birman-Deych et al [31]
and Quan et al [32]. We searched all inpatient, outpatient,
and professional claims for 60 days before through 15
days after the reference serum sodium date for evidence of
cerebrovascular disease (362.34, 430.x-438.x), chronic
obstructive pulmonary disease (416.8, 416.9, 490.x-
505.x, 506.4, 508.1, 508.8), coronary heart disease
(410.x-414.x, 429.2, V45.81), dementia (290.x, 294.1,
331.2), diabetes mellitus (250.x), hypertension (401.x-
405.x, 437.2), kidney disease (403.01, 403.11, 403.91,
404.02, 404.036, 404.12, 404.13, 404.92, 404.93, 582.x,
583.0–583.7, 585.x, 586.x, 588.0, V42.0, V45.1, V56.x),
metastatic carcinoma (196.x-199.x), peripheral vascular
disease (093.0 437.3, 440.x, 441.x, 443.1–443.9, 47.1,
557.1, 557.9, V43.4), and rheumatic disease (446.5,
710.0–710.4, 714.0–714.2, 714.8, 725.x).
We also identified outpatient pharmacy claims for medi-
cations known to cause hyponatremia. We used National
Drug Codes to identify claims for phenothiazines, selec-
tive serotonin reuptake inhibitors, thiazide diuretics, tri-
cyclic antidepressants, prostaglandin synthesis inhibitors,
desmopressin, oxytocin, opiate derivatives, chlorpropa-
mide, clofibrate, carbamazepine, cyclophosphamide, or
vincristine incurred 60 days before through 15 days after
each outpatient serum sodium laboratory date [33].
Finally, for each member with an eligible outpatient
serum sodium laboratory claim, we obtained all outpa-
tient professional claims from 2004 or 2005 that did not
include an ICD-9-CM diagnosis code for hyponatremia.
Statistical analysis
We defined hyponatremia as serum sodium < 136 mmol/
L [1,2,4,33-35]; however, we also performed validity anal-
yses on three additional strata: serum sodium ≤ 133
mmol/L; ≤ 130 mmol/L; and ≤ 125 mmol/L. We used
basic descriptive statistics to summarize demographic
characteristics, comorbidities, and prescription drug claim
information for members with serum sodium values indi-
cating hyponatremia both with and without a corre-
sponding outpatient professional claim for
hyponatremia. We assessed differences between groups
using χ2 tests for categorical variables and Wilcoxon rank
sum tests for continuous variables.
For all measurements of validity, we considered the labo-
ratory result to be the gold standard of diagnosis and the
outpatient professional claim to be the test. We defined
sensitivity as the probability of a positive test–an outpa-
tient professional claim with a primary or secondary ICD-
9-CM diagnosis code of hyponatremia observed within 15
days before or after a serum sodium laboratory result indi-
cating hyponatremia. We defined specificity as the proba-
bility of a negative test–an outpatient professional claim
that did not include an ICD-9-CM code for hyponatremia
or the absence of any outpatient professional claim within
15 days before or after a serum sodium laboratory result
not indicating hyponatremia. Positive predictive value
was the probability of a laboratory result indicating
hyponatremia among positive outpatient professional
claims; negative predictive value was the probability of a
laboratory result not indicating hyponatremia among
negative outpatient professional claims or in the absence
of any outpatient claim.
Using all serum sodium laboratory claims indicating
hyponatremia, we performed logistic regression analysis
to explore the relationships between undocumented
hyponatremia (serum sodium laboratory claim indicating
hyponatremia, but no professional ICD-9-CM claim for
hyponatremia) and members' demographic characteris-
tics and comorbidities as observed within 60 days before
through 15 days after the laboratory encounter.
We used SAS version 9.1.5 for all analyses (SAS Institute
Inc, Cary, NC). The institutional review board of the Duke
University Health System approved this study.
Results
There were 1,901,254 eligible serum sodium laboratory
claims in the study sample. Of these, 40,668 (2.1%) indi-
cated hyponatremia (serum sodium < 136 mmol/L). Out-
patient professional claims with an ICD-9-CM diagnosis
code for hyponatremia were observed within 15 days
before or after the hyponatremic serum sodium lab date
for 1407 of these claims (3.5%) (Table 1).
Mean age of members at the time of the laboratory claim
indicating hyponatremia was 59 years, and over half of all
claims were for women (61%). Hypertension was the
most commonly identified comorbidity in this sample.
Evidence of hypertension during the 60-day period pre-
ceding the laboratory claim date was present for 36.5% of
claims. Diabetes (20.5%), coronary heart disease
(14.4%), and chronic obstructive pulmonary disease
(10.5%) were also observed more frequently than other
conditions. Outpatient pharmacy claims for medications
known to cause hyponatremia were observed within the -
60/+15-day period before or after the laboratory date in 1
of every 4 claims (Table 1).BMC Nephrology 2008, 9:5 http://www.biomedcentral.com/1471-2369/9/5
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Compared to claims without a corresponding diagnosis
code, mean age was greater among outpatient laboratory
claims indicating hyponatremia with an outpatient pro-
fessional diagnosis code for hyponatremia observed
within 15 days (positive test, 67 versus 59 years; p < .001),
and claims were observed significantly more often for
women (61% versus 66%; p = < .001). Evidence of hyper-
tension was observed nearly twice as often during the
period preceding a laboratory claim with a positive test
than for claims with a negative test or with no temporally
adjacent outpatient professional claims (59% versus 36%;
p < .001). Compared to claims that did not have a diagno-
sis code for hyponatremia, claims with a positive test were
also significantly more likely to be observed for members
diagnosed with kidney disease, cardiovascular conditions,
and/or chronic obstructive pulmonary disease; however,
claims with a positive test were significantly less likely to
be observed among members with diabetes or dementia
(Table 1).
Sensitivity for hyponatremia defined as serum sodium <
136 mmol/L was 3.5%; specificity was greater than 99%.
Positive predictive value was 63%, and negative predictive
value was 98% (Table 2). Sensitivity values for the ≤ 133
mmol/L, ≤ 130 mmol/L, and ≤ 125 mmol/L strata were
7.5%, 13.9%, and 29.6%, respectively. Specificity was
greater than 99% for all of the alternative cutoff points
(Table 3).
In the multivariable analysis exploring the relationships
between undocumented hyponatremia and member
demographic characteristics and comorbidities, labora-
tory results indicating hyponatremia among older mem-
bers were significantly more likely to have a
corresponding outpatient professional claim than those
observed for younger members. Controlling for other
comorbid diagnoses, medications known to cause
hyponatremia, and sex, an increase of 10 years in age was
associated with an almost 30% drop in the likelihood of
Table 1: Sample characteristics*
Characteristic Laboratory Claims Indicating Hyponatremia† p||
All Claims (n = 40,668) Negative Test‡ (n = 39,261) Positive Test§(n = 1407)
Age, mean (SD), y 59 (15.7) 59 (15.7) 67 (12.3) < 0.001
Female sex 24,694 (60.7) 23,769 (60.5) 925 (65.7) < 0.001
Underlying conditions and comorbidities
Cerebrovascular disease 1874 (4.6) 1721 (4.4) 153 (10.9) < 0.001
Chronic obstructive pulmonary disease 4279 (10.5) 4020 (10.2) 259 (18.4) < 0.001
Congestive heart failure 2742 (6.7) 2605 (6.6) 137 (9.7) < 0.001
Coronary heart disease 5857 (14.4) 5560 (14.2) 297 (21.1) < 0.001
Dementia 164 (4.0) 141 (3.5) 23 (1.6) < 0.001
Diabetes mellitus 8342 (20.5) 8102 (20.6) 240 (17.1) 0.001
Hypertension 14,825 (36.5) 13,997 (35.7) 828 (58.8) < 0.001
Kidney disease 1491 (3.7) 1405 (3.6) 86 (6.1) < 0.001
Liver cirrhosis 26 (0.1) 24 (0.1) 2 (0.1) 0.24
Metastatic carcinoma 2325 (5.7) 2246 (5.7) 79 (5.6) 0.87
Nephritis, nephrotic syndrome, and nephrosis 1918 (4.7) 1800 (4.6) 118 (8.4) < 0.001
Peripheral vascular disease 1613 (4.0) 1546 (3.9) 67 (4.8) 0.12
Rheumatic disease 1291 (3.2) 1254 (3.2) 37 (2.6) 0.24
Syndrome of inappropriate antidiuretic hormone 157 (3.9) 91 (2.3) 66 (4.7) < 0.001
Medications known to cause hyponatremia 10,492 (25.8) 10,144 (25.8) 348 (24.7) 0.35
* Values are expressed as number (percentage) unless otherwise indicated.
† Hyponatremia was defined as serum sodium < 136 mmol/L.
‡ A negative test was defined as the presence of an outpatient professional claim with no ICD-9-CM code for hyponatremia or the absence of any 
outpatient professional claims within 15 days before or after the laboratory claim indicating hyponatremia.
§ A positive test was defined as the presence of an outpatient professional claim with a primary or secondary ICD-9-CM diagnosis code of 
hyponatremia observed within 15 days before or after the laboratory claim indicating hyponatremia.
|| p-Values for the comparison between the positive and negative test groups.
Table 2: Relationship between ICD-9-CM code documentation 
and laboratory serum sodium < 136 mmol/L
Hyponatremia
+-
ICD-9 = 276.1 + 1407 839
- 39,261 1,859,747
Sensitivity = 3.46%
Specificity = 99.95%
Positive predictive value = 62.64%
Negative predictive value = 97.93%BMC Nephrology 2008, 9:5 http://www.biomedcentral.com/1471-2369/9/5
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a negative claim or no claim at all (odds ratio: 0.74; 95%
confidence interval: 0.66, 0.74; data not shown). Labora-
tory claims preceded by a comorbid diagnosis of cerebrov-
ascular disease, chronic obstructive pulmonary disease,
hypertension, dementia, nephritis/nephrosis, or syn-
drome of inappropriate antidiuretic hormone were also
less likely to be undocumented by a diagnosis code on an
outpatient professional claim. Laboratory claims pre-
ceded by a comorbid diagnosis of diabetes or peripheral
vascular disease were significantly more likely to be
undocumented by a diagnosis code. Claims for medica-
tions known to cause hyponatremia did not have a signif-
icant impact on ICD-9-CM documentation of laboratory-
identified hyponatremia (Table 4).
Discussion
We examined the validity of ICD-9-CM diagnosis codes
for the identification of hyponatremia in an outpatient
managed care population using data from the IHCIS
National Managed Care Benchmark Database. Our results
show that while the ICD-9-CM code for hyponatremia is
highly specific in outpatient claims, its sensitivity is
extremely low. Even for the most severe cases (serum
sodium ≤ 125 mmol/L), we found sensitivity to be less
than 30%. Similarly, the positive predictive value of an
outpatient professional claim for hyponatremia was only
63% using the least strict serum sodium measurement (<
136 mmol/L). These findings are consistent with an ear-
lier study by Movig et al [29], which showed low sensitiv-
ity for the coding of hyponatremia in inpatient settings,
although the positive predictive value of ICD-9-CM codes
in outpatient claims in our study was significantly less
than the corresponding inpatient rates found in the previ-
ous study.
These low rates of coding for hyponatremia may be largely
due to the ICD-9-CM diagnostic coding and reporting
guidelines for outpatient services. According to these
guidelines, only conditions that "require or affect patient
care treatment or management" should be documented.
Moreover, "related signs and symptoms" should not be
coded when a more definitive diagnosis is known [36].
Thus, at mildly decreased levels requiring no medical
intervention and/or in the presence of causal underlying
disease such as syndrome of inappropriate antidiuretic
hormone or liver cirrhosis, it may be inappropriate to
code for hyponatremia on an outpatient claim. Similarly,
there may be limited space available for diagnoses on the
Table 3: Validity measures by laboratory serum sodium values
Serum Sodium (mmol/L)
< 136 ≤ 133 ≤ 130 ≤ 125
Sensitivity 3.46 7.50 13.85 29.57
False-negative rate 96.54 92.50 86.15 70.43
Specificity 99.95 99.94 99.92 99.90
False-positive rate 0.05 0.06 0.08 0.10
Positive predictive value 62.64 48.74 30.00 10.42
Negative predictive value 97.93 99.28 99.78 99.97
Table 4: Likelihood of a negative test for claims indicating hyponatremia*
OR 95% CI
Age in years 0.97 0.96, 0.97
Female 0.75 0.67, 0.85
Underlying conditions and comorbidities
Cerebrovascular disease 0.61 0.50, 0.73
Chronic obstructive pulmonary disease 0.62 0.54, 0.72
Congestive heart failure 1.09 0.89, 1.34
Coronary heart disease 0.98 0.84, 1.14
Dementia 0.44 0.27, 0.70
Diabetes mellitus 1.47 1.27, 1.70
Hypertension 0.53 0.47, 0.59
Kidney disease 1.24 0.84, 1.83
Liver cirrhosis† 0.31 0.07, 1.38
Metastatic carcinoma 1.11 0.87, 1.41
Nephritis, nephrotic syndrome, and nephrosis 0.49 0.35, 0.69
Peripheral vascular disease 1.40 1.08, 1.82
Rheumatic disease 1.27 0.91, 1.77
Syndrome of inappropriate antidiuretic hormone 0.06 0.04, 0.08
Medications known to cause hyponatremia 1.08 0.95, 1.22
* Hyponatremia was defined as serum sodium < 136 mmol/L. A negative test was defined as the presence of an outpatient professional claim with 
no ICD-9-CM code for hyponatremia or the absence of any outpatient professional claims within 15 days before or after the laboratory claim 
indicating hyponatremia.
† Indicates that the condition was present in < 1% of the population.
Abbreviations: OR indicates odds ratio; and CI, confidence interval.BMC Nephrology 2008, 9:5 http://www.biomedcentral.com/1471-2369/9/5
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outpatient claim form. The IHCIS database, for example,
allows for a maximum of 3 diagnosis codes on each pro-
fessional claim record. As shown in Table 1,
hyponatremia is often seen in the presence of other signif-
icant comorbidities. Given that ICD-9-CM coding guide-
lines also specify that one should "list first the ICD-9-CM
code for the diagnosis, condition, problem, or other rea-
son for encounter/visit shown in the medical record to be
chiefly responsible for the services provided" [36], other
conditions may have taken precedence on the claim form.
The clinical consequences of even mild hyponatremia are
well-documented [3,4,6,34,35,37-39]. In a cohort of eld-
erly patients, hyponatremia at hospital admission was a
significant independent predictor of mortality after
adjustment for age, sex, length of stay, and several clinical
factors [7]. Hyponatremia (serum sodium ≤ 135 mmol/L)
is independently associated with major complications,
greater length of stay, higher hospital costs, and greater
inpatient mortality in patients with suspected congestive
heart failure [1] and with greater in-hospital and 60-day
mortality in patients with heart failure [2]. It is an inde-
pendent predictor of 30-day mortality in patients with
acute ST-segment elevation myocardial infarction [3].
Given the preponderance of evidence suggesting that
hyponatremia is an independent predictor of poorer out-
comes, our findings suggest that the prognostic value of
even severe hyponatremia may be underappreciated.
Another potential explanation for the low observed rates
of coding is that hyponatremia, as identified by a single
laboratory value, may have been a transient condition for
some members. We analyzed single laboratory values and
did not consider the results of prior or subsequent testing.
Thus, it is possible that some members received follow-up
testing that showed the condition to be resolved, thereby
eliminating the need for documentation on the outpa-
tient professional claim. Also, because the sample
included commercially insured adults with relatively low
amounts of comorbid illness, mildly decreased levels of
serum sodium may not be clinically significant or require
medical intervention. Nevertheless, we found sensitivity
to be less than 30%, even in the case of serum sodium ≤
125 mmol/L. Finally, because documentation of
hyponatremia is unlikely to generate additional reim-
bursement for outpatient services, there may be little
incentive for physicians to include it on the claim.
In contrast, the positive predictive value of outpatient
claims for hyponatremia was also low (63% for serum
sodium < 136 mmol/L). This finding may reflect the fact
that hyponatremia is a chronic condition for some
patients and is therefore likely to be noted on outpatient
professional claims despite the fact that there are no
observable laboratory claims within +/-15 days to support
the diagnosis. The data used here, however, do not
include sufficient detail to validate this hypothesis.
Although the impact of medications known to cause
hyponatremia was not significant in the multivariable
model, there was a trend toward less ICD-9-CM documen-
tation of laboratory-identified hyponatremia in the pres-
ence of this factor. Outpatient claims for medications
known to cause hyponatremia were observed within 60
days before through 15 days after 25% of all laboratory
claims indicating hyponatremia. This finding suggests
that some clinicians may choose not to code
hyponatremia when it may be the result of drug therapy.
Other results of the multivariable model also suggest that
ICD-9-CM coding of laboratory-identified hyponatremia
may be especially poor for patients with peripheral vascu-
lar disease or diabetes. Claims for members with these
conditions were more than 40% less likely to have an
ICD-9-CM code for hyponatremia.
This study has some limitations. First, outpatient labora-
tory data are only available for approximately 10% of
members in the IHCIS database. Second, the IHCIS data-
base consists of managed care claims only and is therefore
representative of an employer-based, commercially
insured population. We expect that the elderly are signifi-
cantly underrepresented in the database. Because the risk
of hyponatremia is highest among the elderly and our
results show that the frequency of coding for
hyponatremia increases with age, our findings may not be
generalizable to older populations. Inconsistent and inac-
curate coding and the absence of clinical data regarding
disease severity may have also affected our estimates. We
required just 60 days of continuous coverage before and
15 days of coverage after the reference serum sodium date
and searched for evidence of comorbidity claims within
that time period only. Although this approach maximized
our sample size, it also limited the available time frame in
which we could observe comorbid illnesses, which may
have led to an underestimation of these conditions in our
analyses. We also chose to search for outpatient profes-
sional claims that were temporally adjacent to serum
sodium laboratory tests (+/-15 days). As a result, the anal-
ysis is unable to capture instances where abnormal test
results were addressed by providers without generation of
an outpatient claim (eg, by phone or e-mail) or when a
follow-up visit was performed outside of this time win-
dow. Finally, the study used outpatient clinical and labo-
ratory information only. The results do not account for
the possibility that a laboratory-identified diagnosis of
hyponatremia, for example, may have been documented
by an ICD-9-CM code on an inpatient claim just before or
after the outpatient laboratory date.BMC Nephrology 2008, 9:5 http://www.biomedcentral.com/1471-2369/9/5
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Conclusion
Our results suggest that the use of ICD-9-CM codes in
administrative data alone is insufficient to identify
hyponatremia in outpatient populations. Whenever pos-
sible, supplementary laboratory information should be
used to help overcome this limitation of administrative
claims.
Abbreviations
CI: confidence interval; ICD-9-CM: International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification;
IHCIS: Integrated Healthcare Information Services; OR:
odds ratio.
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